 Recently in the investigators hospital a case of diffuse large B-cell lymphoma DLBCL was initially misdiagnosed as NET because of high uptake of 68Ga-DOTANOC in pancreatic tumor at PETCT. A PubMed search revealed a similar case report in bronchial tumor which turned out to be DLBCL Jain et al. Clin Nucl Med 2014;39:358-359. Bearing these two cases in mind the investigators now aim to systematically study somatostatin receptor status ssr by measuring uptake of 68Ga-DOTANOC with PETCT in patients with newly diagnosed non-Hodgkins and Hodgkins lymphoma. The imaging findings will be compared to immunohistochemically determined ssr-subtypes 2,3 and 5 obtained from pre-treatment fresh tumor samples and 18F-FDG PETCT which is part of standard diagnostic evaluation. Furthermore, whole-body MRI with DWI will be performed before, during and after chemotherapy to define the most sensitive and specific imaging method appropriate for routine diagnosis and follow-up. This study has potential implications for future response monitoring and follow-up imaging techniques in patients with malignant lymphoma and provides additional biologic characterization which may be useful for novel therapeutic approaches such as PRRT. 